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Abstract
Background: Coronary heart disease (CHD) and depression are leading causes of disease burden globally and the
two often co-exist. Depression is common after Myocardial Infarction (MI) and it has been estimated that 15-35%
of patients experience depressive symptoms. Co-morbid depression can impair health related quality of life
(HRQOL), decrease medication adherence and appropriate utilisation of health services, lead to increased morbidity
and suicide risk, and is associated with poorer CHD risk factor profiles and reduced survival. We aim to determine
the feasibility of conducting a randomised, multi-centre trial designed to compare a tele-health program
(MoodCare) for depression and CHD secondary prevention, with Usual Care (UC).
Methods: Over 1600 patients admitted after index admission for Acute Coronary Syndrome (ACS) are being
screened for depression at six metropolitan hospitals in the Australian states of Victoria and Queensland.
Consenting participants are then contacted at two weeks post-discharge for baseline assessment. One hundred
eligible participants are to be randomised to an intervention or a usual medical care control group (50 per group).
The intervention consists of up to 10 × 30-40 minute structured telephone sessions, delivered by registered
psychologists, commencing within two weeks of baseline screening. The intervention focuses on depression
management, lifestyle factors (physical activity, healthy eating, smoking cessation, alcohol intake), medication
adherence and managing co-morbidities. Data collection occurs at baseline (Time 1), 6 months (post-intervention)
(Time 2), 12 months (Time 3) and 24 months follow-up for longer term effects (Time 4). We are comparing
depression (Cardiac Depression Scale [CDS]) and HRQOL (Short Form-12 [SF-12]) scores between treatment and UC
groups, assessing the feasibility of the program through patient acceptability and exploring long term maintenance
effects. A cost-effectiveness analysis of the costs and outcomes for patients in the intervention and control groups
is being conducted from the perspective of health care costs to the government.
Discussion: This manuscript presents the protocol for a randomised, multi-centre trial to evaluate the feasibility of
a tele-based depression management and CHD secondary prevention program for ACS patients. The results of this
trial will provide valuable new information about potential psychological and wellbeing benefits, cost-effectiveness
and acceptability of an innovative tele-based depression management and secondary prevention program for CHD
patients experiencing depression.
Trial Registration Number: Australia and New Zealand Clinical Trials Register (ANZCTR): ACTRN12609000386235
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Coronary Heart Disease (CHD) and depression are cur-
rently two of the most important causes of disability in
high-income countries [1] and it is projected that the
same will apply to low and middle income countries by
2030 [2]. These conditions often co-exist with approxi-
mately 15% of Myocardial Infarction (MI) patients
experiencing major depressive disorder (MDD) and
another 15-20% exhibiting mild to moderate depression
[3]. Patients with post-MI depression are more likely to
report impaired health related quality of life (HRQOL)
[4], poorer medication adherence [5] and utilisation of
health services [6], increased morbidity and suicide risk
[7], and poorer CHD risk factor profiles, work outcomes
[8] and survival [9]. In particular, depression results in
poor uptake and completion of CHD secondary preven-
tion or cardiac rehabilitation programs [10], which have
been shown to play a pivotal role in improving CHD
risk factor profiles and other clinical outcomes. Indeed,
compared with non-depressed patients, depressed
patients are three times less likely to be compliant with
medical treatment recommendations [11]. The clinical
benefits of CHD secondary prevention programs are
well documented and include decreased risk of fatal and
non-fatal recurrent MI and CVD [12], improved
HRQOL, and lower rates of rehospitalisation [13,14].
However, despite the high prevalence of depression fol-
lowing a diagnosis of CHD and the poor outcomes asso-
ciated with the group [9], it remains poorly recognised
and managed in CHD patients.
Traditionally, CHD secondary prevention programs are
delivered face-to-face in clinic- or hospital-based settings;
however, they suffer from low participation rates due to a
range of barriers including poor accessibility and access
[15]. Symptoms of depression following Acute Coronary
Syndrome (ACS) - including hopelessness, helplessness,
and apathy - can further impede participation in second-
ary prevention programs. Contemporary approaches to
CHD secondary prevention may help to overcome this
treatment gap. A recent meta-analysis demonstrated that
innovative, tele-based CHD secondary prevention pro-
grams may transcend some of the barriers to participa-
tion in traditional rehabilitation programs, and they are
effective in improving behavioural and clinical outcomes
for cardiac patients [16]. Further, telephone-delivered
therapy has proven effective for patients with depression
[17] and more recently, for those with co-morbid depres-
sion following a cardiac event. For example, a tele-health,
nurse-delivered, collaborative care intervention for cor-
onary artery bypass graft surgery patients suffering from
depression significantly improved depression outcomes,
mental health components of HRQOL and disease speci-
fic physical functioning [18].
Psychological based therapies [19,20], pharmacologic
approaches (namely Selective Serotonin Reuptake Inhi-
bitors) [21], and composite approaches to treatment
[22,23] have all demonstrated improvements in depres-
sion for CHD patients, especially for those with recur-
rent depression [24]. While pharmacologic and
psychological approaches have yielded comparable effect
sizes in reducing depression [25], Cognitive Behaviour
Therapy (CBT) has been shown to be particularly
favourable for improving depression outcomes for car-
diac patients, with an American Heart Association
report endorsing its use [26]. Evidence from a number
of well designed trials also demonstrate its effectiveness
in reducing depression in cardiac patients when com-
pared with other approaches [19]. For example, com-
pared to usual care (UC), Freedland and colleagues
(2007) demonstrated that CBT displayed greater and
more durable effects than the other approaches [19].
However, relatively little is known about its effectiveness
under ‘real world’ delivery conditions, particularly using
a tele-based approach.
The feasibility of combining a tele-health, depression
management program using CBT with a CHD secondary
prevention program for ACS patients is yet to be estab-
lished in the ‘real world’ setting. The effects of such a
program could go beyond treating depression to improve
all aspects of HRQOL and CHD risk factors, and demon-
strate significant economic advantages over more tradi-
tional modes of delivery. This paper presents the study
protocol for a randomised, multi-centre, feasibility trial
of a tele-health intervention for ACS patients with
depression (’MoodCare’). We hypothesise that the trial
will demonstrate the feasibility of the MoodCare inter-
vention through improving key depression and HRQOL
outcomes at 6 months, with increased participant satis-
faction, and will be cost-effective compared with UC.
Methods
We are currently enrolling 100 ACS patients in a pro-
spective, multi-centre, feasibility trial with patients ran-
domised to either the intervention or UC control group.
Participants in both groups complete assessments at
baseline (Time 1), post-intervention or 6 months follow-
up (Time 2), as well as at 12 months (Time 3), and
24 months (Time 4) for longer term effects.
Study Aims
Primary Aim
To investigate the feasibility of a telephone-delivered,
depression management and CHD secondary prevention
intervention for ACS patients over 6 months. Prospective
outcomes include: changes in depression using the Car-
diac Depression Scale (CDS) and changes in HRQOL
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participant acceptability compared with UC.
Secondary Aims
(i) To investigate the longer term feasibility of imple-
menting the MoodCare program at 12 and 24 months
follow-up.
Study Sample
Eligibility Criteria
Eligibility criteria includes: a clinical diagnosis consistent
with that of ACS (MI [STEMI or non STEMI] or
unstable angina confirmed by angiogram), aged 21-85
years, fluency in English, availability via the telephone
for the duration of the study, and a Patient Health
Questionnaire (PHQ9) score of 5-19. Patients are
excluded if they are: participating in regular psychologi-
cal therapy with a mental health professional at the time
of admission for ACS, diagnosed with a psychiatric con-
dition which may impact on involvement (including
bipolar disorder, psychotic illness of any type, dementia,
acute suicidality, severe personality disorder), cognitively
impaired impacting on their ability to participate in the
study, diagnosed with a terminal illness, or unable to
participate in a tele-based unsupervised mood and life-
style intervention as confirmed by the treating clinician.
Sample Recruitment Procedures
We are screening more than 1600 patients over approxi-
mately 15 months from six metropolitan hospitals in
Victoria and Queensland, Australia. Recruitment com-
menced in December 2009. All consenting patients are
assessed for depression prior to hospital discharge using
a psychometrically robust and valid instrument (PHQ9)
[27]. Patients with a PHQ9 score of 5-19 are eligible to
participate. This scoring range was selected due to its
high sensitivity and specificity, as opposed to the com-
monly used cut off of ≥ 10, which has comparable speci-
ficity (92% and 90%, respectively), but poorer sensitivity
(39% and 54%, respectively) [28]. Patients with a PHQ9
score <5 are provided with relevant feedback, reassur-
ance and advice. Any persons indicating suicidal
thoughts on PHQ9 and/or those with severe depression,
as indicated by PHQ9 scores of 20-27, are referred for
further assessment by a mental health professional and
possible study exclusion. Algorithms are in place for
patients assigned to the intervention whose condition
deteriorates throughout the program, and who are no
longer eligible or lost to follow up throughout the
course of the trial.
Eligible participants are subsequently contacted by
the research team via telephone within 1-2 weeks of
discharge to complete Time 1 data collection. This
includes a secondary assessment of depression in order
to determine severity. Participants initially respond to
a two item screening tool which has a positive
endorsement of the first two PHQ items [28], before
undertaking the full Composite International Diagnos-
tic Interview (CIDI) assessment.
Sample Size Calculations
Anticipating an attrition rate of 20% throughout the
study, n = 125 participants are required to achieve a
final sample size of n = 100. Sample size analysis indi-
cated that 50 subjects per group (intervention and con-
trol) or a total of 100 are required to complete the
study in order to detect an absolute intervention effect
with 80% power and type I error of 5% (two-tailed).
Sample size was calculated based on an overall differ-
ence between participants in the intervention and
control groups in the primary outcome measure of
depression scores at 6 months, where a sample size of
n = 100 was sufficient to det e c tad i f f e r e n c ei nm e a n
CDS scores of 6.8, assuming a between-patient SD of 12
[29]. Assuming persistence of effect to 12 months and a
conservative correlation of0 . 3 0b e t w e e nb a s e l i n e ,6
months and 12 months CDS scores, a pooled analysis at
6 and 12 months will have 80% power to detect a differ-
ence of 5.1 units (a change score of 5 on the CDS is
considered clinically meaningful).
Ethics Approval
Ethics approval was received from Human Research
Ethics Committees of St Vincent’s Hospital, The Austin
Hospital, The Royal Melbourne Hospital, The Geelong
Hospital, The Prince Charles Hospital, The Royal Bris-
bane and Women’s Hospital, and Monash University.
Study conditions
Both control and intervention participants receive a
brief National Heart Foundation of Australia education
pamphlet on MI recovery and a biennial study newslet-
ter based on existing educational materials to enhance
study retention. On enrolment, a letter is sent to all par-
ticipants’ primary care provider/s informing them of the
aims of the study, the group to which the patient has
been randomised and other relevant information that
may be required from the participant and the care pro-
vider at follow-up.
Control
Control participants continue to receive their usual
medical care through their health care providers.
Intervention
The intervention commences within two weeks of base-
line screening and is delivered by qualified psychologists
(‘counsellors’) from Monash University. The interven-
tion aims to manage depression as well as CHD risk
factor behaviours using a tele-based care management
model [30] incorporating CBT counselling [31]. Two
psychologists with at least 2 years of relevant clinical
experience with CBT are delivering the intervention.
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telephone during structured counselling sessions and
assist participants to set and attain specific short and
long term goals and a plan of action to improve their
mental health and CHD risk factor profiles. Cognitive
restructuring, behavioural activation, goal setting and
motivational interviewing techniques are utilised. Parti-
cipants are encouraged to seek appropriate treatment
and attend follow-up with their usual health care provi-
ders as necessary, in addition to activating social/family
support and community and environmental linkages
(e.g. employment, housing support). The intervention
comprises up to 10 × 30-40 minute sessions over a six
month period as CBT has been found to effectively
reduce depressive symptoms over this time frame [22].
The sessions are most intensive over the first three
months when depressive symptoms are most likely to
affect patients following ACS [32] and to impact on
their HRQOL and adoption of positive CHD risk factor
behaviours. More frequent sessions may be scheduled
during the treatment phase based on a patient’sn e e d s
and interest but the intervention is limited to up to 10
sessions in total.
Intervention participants receive a handbook contain-
ing both project specific and general health resources.
For example, the handbook contains monitoring forms
and recording sheets to be used during and in between
sessions for tracking the participant’s mood, session
activities, the participant’s thoughts, CHD risk factor
goals and changes. It provides additional information
and details on the nature and treatment of depression,
as well as the CBT model. More generally, supplemen-
tary materials including a list of health related resources
are provided in the handbook.
Study Integrity
The study design is guided by the CONSORT statement
[33] and randomisation to study group occurs following
the completion of Time 1 data collection. Project staff
who are collecting data are blinded to participants’
group allocation. Participants are asked not to reveal the
group to which they have been randomised when com-
pleting data assessments. Stratified randomisation occurs
using a separate block randomisation list that has been
generated for each study group or strata. Randomisation
is integrated into the web-based database and automati-
cally generated following the conclusion of baseline
assessment. The process is concealed from investigators.
The schedule is stratified by severity of depression
assessed by the CIDI (i.e. those meeting current diagno-
sis for depression versus those who do not). The inter-
vention protocol is detailed in a manual. In addition to
internal peer review, all intervention calls are audio-
taped with a proportion reviewed by a senior clinical
psychiatric consultant, using a standardised inventory in
order to ensure clinicians’ adherence to the delivery of
the intervention protocol and treatment integrity. To
assess the quality of the delivery of the intervention, a
separate inventory based on the Cognitive Therapy Scale
[34] has been developed for the MoodCare intervention.
All data analyses are conducted on the basis of intention
to treat.
Data collection and outcome measures
Clinical and anthropometric data are collected at the
time of the participant’s initial screening, from hospital
medical records (blood pressure, cholesterol level, hae-
moglobin A1C (HbA1c), family history of heart disease,
height, weight, waist circumference, body mass index
(BMI), procedures performed or scheduled, General
Practitioner (GP) details, cardiologist details, whether
patient was transferred from another hospital, details of
initial admitting hospital, admission and expected dis-
charge date). At follow-up, participants are requested to
collect medical information (blood pressure, cholesterol
level, HbA1c, weight, waist circumference) from their
primary care provider/s medical records prior to Com-
puter Assisted Telephone Interview (CATI). Self-report
and CIDI interview data are collected, at Time 1, Time
2, Time 3 and Time 4 by CATI. Additional outcome
d a t aa r ec o l l e c t e dv i ap o s t a ls u r v e yt om i n i m i s ep a r t i c i -
pant burden (see Table 1). The feasibility of the trial
will be determined by the following outcome measures:
Changes in key depression and HRQOL outcomes
The two primary outcomes are changes in depression
and HRQOL which are assessed using the CDS [35]
and SF-12 [36], respectively. The CDS was originally
designed to measure depressed mood over the full
range generally seen in cardiac patients, combining
excellent test-retest reproducibility with responsiveness
to change over time [29]. In addition, it also has excel-
lent sensitivity (97%) and appropriate specificity (85%)
for the categorical diagnosis of major depression [37].
Other outcome variables include: physical activity [38],
saturated fat intake [39], smoking, alcohol intake [40],
anxiety [41], social support, employment, lipid profile,
blood pressure, BMI, waist circumference, diabetes
management (HbA1c), and pharmacological manage-
ment (self report, health care utilisation data). Six
month follow up will be the primary assessment point.
The measures for each of these outcome variables are
summarised in Table 1.
Cost-Effectiveness Analyses
A cost-effectiveness analysis (CEA) of the costs and out-
comes for patients in the intervention and control
groups will be undertaken. Detailed data on costs of
Health Care Utilisation (HCU), access to community
and other resources and medication are being collected
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groups. All resources utilised are costed using nationally
applicable cost data (e.g. Diagnostic Related Groups
costs for hospital admissions). Total medication costs
are taken from patient contributions and estimated total
Pharmaceutical Benefits Scheme benefits paid by the
Health Insurance Commission. For HCU, data linkage
with Medicare Australia’s database allows the collection
of health care utilisation data for use of items under
Medicare and Pharmaceutical Benefits Scheme (PBS).
Participants are requested to record current medications
and number of general practitioner visits prior to Time
3 and Time 4 follow-up assessments.
The expected cost of readmission for ACS is also cal-
culated using hospital-based costs and patient-specific
probabilities of readmission for ACS computed using
APACHE III (Acute Physiology And Chronic Health
Evaluation III). The primary health outcome for the
CEA is quality-adjusted life years (QALYs). These are
calculated for both arms using HRQOL scores collected
in the trial using the SF-6D, a derivative of the SF-12.
The SF-12 instrument is widely used internationally,
and has been recommended as appropriate and sensitive
to change for CHD patients and in depression treatment
[42]. For all economic analyses, detailed probabilistic
sensitivity analysis will be undertaken for all projections
and parameters with uncertainty and/or variability.
Intervention Implementation and Acceptability
To assess program implementation, participant accept-
ability is measured by a self-administered questionnaire
at Time 2. Self-administered satisfaction questions
include: ‘how would you rate the MoodCare Participant
Handbook’ (excellent to poor); ‘how would you rate your
sessions with the Counsellor (very useful to not useful at
all); ‘did you get what you expected from the program’
(yes definitely to no definitely not); ‘to what extent has
the program met your needs’ (almost all of my needs
have been met to none of my needs have been met); ’has
the program helped you to deal more effectively with
your health issues’ (yes it helped a great deal to no it
seemed to make things worse); ‘in general how satisfied
are you with the program (very satisfied to very dissatis-
fied); ‘were you satisfied with the length of the counsel-
ling sessions’ (yes, no); ‘were you satisfied with the
number of counselling sessions’ (yes, no);a n d‘were you
satisfied with the length of the program overall’ (yes,
no). Participants are also asked to highlight the strengths
and weaknesses of the program in two open-ended
Table 1 Measurement of outcome variables at baseline (Time 1), post-intervention (Time 2), 12 months (Time 3),
24 months follow-up (Time 4)
Variable Measurement tool Inpatient
Screening
1-2
weeks
post
discharge
TIME 1
6
Months
TIME 2
12
Months
TIME 3
24
months
TIME 4
Type of
administration
Depression Patient Health Questionnaire 9 ✓✓ ✓ ✓ ✓CATI
+
Two item screener [28] ✓ CATI
Cardiac Depression Scale ✓✓ ✓ ✓ CATI
Composite International Diagnostic Interview ✓✓ ✓ CATI
HRQOL Short Form 12 ✓✓ ✓ ✓ CATI
Physical activity Active Australia Survey ✓✓ ✓ ✓ Postal survey*
Saturated Fat Intake Short Fat questionnaire ✓✓ ✓ ✓ Postal survey*
Social Support ENRICHD Social Support Inventory ✓✓ ✓ ✓ CATI
Smoking Cancer Council Food Frequency Questionnaire ✓✓ ✓ ✓ Postal survey*
Alcohol Cancer Council Food Frequency Questionnaire ✓✓ ✓ ✓ Postal survey*
Medication Self report/General Practitioner/data linkage ✓✓ ✓ ✓ Postal survey,*
medical records
Anxiety General Anxiety Disorder-7 ✓✓ ✓ ✓ CATI
Medical co-morbidities ✓✓ ✓ ✓ CATI
Biomedical and
anthropometric
measurements
Weight, height, waist circumference, Blood
Pressure, lipids, fasting capillary blood glucose
✓✓ ✓ Medical records
Employment Employment status, absenteeism/productivity ✓✓ ✓ ✓ CATI
CATI = Computer Assisted Telephone Interview; *An envelope containing self administered paper copies of each instrument is posted to the participant prior to
their baseline telephone interview. The survey is to be completed on approximately the same day as baseline CATI interview to ensure consistency of
information, and returned to the Project Manager.
+ In patient screening conducted face to face by nurses, using the PHQ9. Follow up PHQ9 administered via
CATI at all assessment points thereafter.
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assessed by: the proportion of sessions completed during
the intervention period; the topics covered in each ses-
sion; and the total length (minutes) of intervention
exposure during the six month period.
Long term maintenance and sustainability
The RE-AIM framework has been developed to evaluate
the strengths and weaknesses of different approaches to
chronic disease management [43]. This framework will
be applied to further assess the feasibility of the Mood-
Care program. For example, we will evaluate the Reach,
or representativeness of the sample by assessing the
characteristics of eligible, enrolled and randomised parti-
cipants. Similarly, to assess Adoption, characteristics on
program uptake and adherence will be provided. The
long term Maintenance of the program will be assessed
by evaluating participant outcomes beyond six month
follow up (e.g. 12, 24 months).
Data Analyses
Baseline characteristics will be compared across inter-
vention arms using summary statistics. Principal ana-
lyses will involve comparison of CDS and HRQOL
outcomes at each time point between intervention arms
using the baseline of the outcome as a covariate where
relevant. Pooled analyses across all time points will
employ linear mixed models. This will assess compara-
tive rates of change over time, variability between rates
of individuals, and allows for incomplete data due to a
process of missingness where systematic dependence is
upon observed covariates or outcomes, the so called
“missing at random” assumption. Results will be
expressed as estimated mean changes in CDS depression
measures and HRQOL, as an overall mean excess inter-
vention over usual care effect, all with corresponding
95% confidence intervals.
Discussion
Depression often remains unrecognised and untreated in
cardiac patients, despite increasing the risk of poor
patient outcomes such as reduced HRQOL and increased
mortality (including suicide). For the first time, this study
will evaluate the feasibility, efficacy and cost-effectiveness
of a state-of-the-art, tele-based depression management
and CHD secondary prevention program for depressed
ACS patients. If feasible and successful in promoting
depression and HRQOL benefits, the intervention could
provide an alternative for those who cannot tolerate or
would prefer a non-pharmacological alternative to
depression treatment. Further, this contemporary tele-
health approach to management may help overcome
some of the barriers to participation that are associated
with face to face rehabilitation programs, including dis-
tance, cost and time. The intervention could be
translated into clinical practice through community-
based telephone helplines widely used in Australia and
internationally or through acute clinical care settings.
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